ClinicalTrials.gg
CompletedNCT02319044Updated Sep 29, 2020Results posted

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

A Phase 2 interventional study of MEDI4736 and Tremelimumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck, sponsored by AstraZeneca. Completed at 125 sites in 15 countries. Open to participants aged 18 Years to 96 Years. Per ClinicalTrials.gov, last updated 2020-09-29.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years to 96 Years
Sex
All
01

Study summary

The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of the head and neck who have progressed during or after treatment with a platinum containing regimen for recurrent/metastatic disease.

Read the detailed description

This is a randomized, open-label, multi-center, global, Phase II study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy, MEDI4736 monotherapy and tremelimumab monotherapy in the treatment of patients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck (SCCHN) who have progressed during or after treatment with only 1 systemic palliative regimen for recurrent or metastatic disease, that must have contained a platinum agent.

Patients will be randomized in a stratified manner according to prognostic factors, including human papillomavirus (HPV) status and smoking status to achieve a balance between treatments for each of the factors. Patients will be randomized in a 1:1:2 fashion to receive MEDI4736 monotherapy, tremelimumab monotherapy, or MEDI4736 + tremelimumab combination.

All treatments will be administered beginning on Day 0 for 12 months or until confirmed progression of disease; unless, in the Investigator's opinion, the patient continues to receive benefit from the treatment), initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. Patients with confirmed progression of disease who, in the Investigator's opinion, continue to receive benefit from their assigned investigational product and who meet the criteria for treatment in the setting of progression of disease may continue to receive their assigned investigational product treatment for a maximum of 12 months after consultation with the Sponsor and at the Investigator's discretion. The monotherapy arms (tremelimumab and MEDI4736) should be discontinued if there is confirmed progression of disease following a previous response in target lesions (complete response or partial response).

Tumor assessments will be performed using computed tomography or magnetic resonance imaging. Efficacy for all patients will be assessed by objective tumor assessments every 8 weeks (q8w) for the first 48 weeks (relative to the date of the first infusion) then q12w in patients who have disease control after 12 months until confirmed objective disease progression.

Following completion or discontinuation of treatment, patients will enter a follow-up period.

02

Conditions studied

  • Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

Browse trials for

Keywords

  • Head and neck cancer; SCCHN
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 96 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years;
  • Written obtained from the patient/legal representative;
  • confirmed recurrent or SCCHN; tumor progression or recurrence during or after treatment with only 1 systemic palliative regimen for recurrent or metastatic disease that must have contained a platinum agent; Patients who have only received chemo-radiation with curative intent for treatment of their locally advanced disease or recurrent disease are not eligible. Patients who received concurrent chemo-radiation as part of treatment of their recurrent disease are also not eligible.
  • Written consent to provide newly acquired tumor tissue (preferred) or for the purpose of establishing status.
  • Confirmed PD-L1-negative SCCHN by Ventana SP263;
  • performance status of 0 or 1;
  • At least 1 at baseline;
  • No prior exposure to immune-mediated therapy;
  • Adequate organ and marrow function; Evidence of status or negative urinary or serum pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • confirmed squamous cell carcinoma of any other primary anatomic location in the head and neck;
  • Received more than 1 regimen for recurrent or disease
  • Any concurrent chemotherapy, Product, biologic, or hormonal therapy for cancer treatment;
  • Receipt of any investigational anticancer therapy within 28 days or 5 half-lives;
  • Receipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatment;
  • Major surgical procedure within 28 days prior to the first dose of Investigational Product;
  • Any unresolved toxicity Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterion;
  • Current or prior use of medication within 14 days before the first dose of their assigned Investigational Product;
  • History of allogeneic organ transplantation;
  • Active or prior documented or inflammatory disorders;
  • Uncontrolled intercurrent illness;
  • another primary
  • Patients with history of , spinal cord compression, or a history of ;
  • History of active primary immunodeficiency;
  • Known history of previous tuberculosis;
  • Active infection including , or (HIV);
  • Receipt of live, attenuated vaccine within 30 days prior to the first dose of Investigational Product;
  • Pregnant or breast-feeding female patients;
  • Mean corrected for heart rate (QTc) ≥470 ms calculated from 3 (ECGs) using Fridericia's Correction
  • Known allergy or to Investigational Product.
  • Any condition that, in the opinion of the Investigator, would interfere with evaluation of the IP or interpretation of patient safety or study results
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    MEDI4736

    MEDI4736 monotherapy

    Drug: MEDI4736

  • Experimental
    Tremelimumab

    Tremelimumab monotherapy

    Drug: Tremelimumab

  • Experimental
    MEDI4736 + Tremelimumab

    MEDI4736 + Tremelimumab combination therapy

    Drug: MEDI4736 + Tremelimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate at 6 Months

    Objective response rate, primary analysis, based on BICR assessments according to RECIST v1.1. The number (%) of patients with a response excludes unconfirmed responses

    Time frame: After 6 months

  2. Objective Response Rate at 12 Months

    Objective response rate (per RECIST 1.1 as assessed by blinded independent central review \[BICR\]) is defined as the number (%) of patients with a confirmed complete response or confirmed partial response and will be based on all treated patients who are PD-L1-positive with measurable disease at baseline per BICR. Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1. criteria are: Complete response \[CR\] = disappearance of all target lesions since baseline; and partial response \[PR\] = at least a 30% decrease in the sum of the diameters of target lesions.

    Time frame: After 12 months

Secondary outcomes

  1. Best Objective Response

    The best response a patient has had during their time in the study

    Time frame: After 12 months

  2. Duration of Response - Participants Remaining in Response

    Participants remaining in response - based on BICR assessments according to RECIST v1.1. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off.

    Time frame: After 12 months

  3. Time to Response

    Time to response in patients with objective response based on BICR assessments according to RECIST 1.1

    Time frame: After 12 months

  4. Time to Onset of Response From First Dose

    Time to onset of response in patients with objective response based on BICR assessments according to RECIST 1.1

    Time frame: After 12 months

  5. Disease Control Rate (DCR)

    Disease control rate (DCR) at 6 months based on BICR assessments according to RECIST v1.1. DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD). -Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following randomization. -Method 2: Patients who had a best objective response of CR or PR in the first 24 weeks or who had demonstrated SD for a minimum interval of 16 weeks following randomization.

    Time frame: After 6 months

  6. Disease Control Rate (DCR)

    Disease control rate (DCR) at 12 months based on BICR assessments according to RECIST v1.1. DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD). -Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following randomization. -Method 2: Patients who had a best objective response of CR or PR in the first 24 weeks or who had demonstrated SD for a minimum interval of 16 weeks following randomization.

    Time frame: After 12 months

  7. Progression-free Survival (PFS)

    Progression status at 6 months based on BICR assessments according to RECIST v1.1 at time of Progression Free Survival (PFS) analysis. Progression was defined as the time from the data of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. -Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. -Progression death refers to death in the absence of RECIST 1.1 progression.

    Time frame: After 6 months

  8. Progression-free Survival (PFS)

    Progression status at 12 months based on BICR assessments according to RECIST v1.1 at time of Progression Free Survival (PFS) analysis. Progression was defined as the time from the data of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. -Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. -Progression death refers to death in the absence of RECIST 1.1 progression.

    Time frame: After 12 months

  9. Overall Survival

    Survival status at time of overall survival analysis. 'Still in survival follow-up' includes patients known to be alive at data cut-off. 'Terminated prior to death' includes patients with unknown survival status or patients who were lost to follow-up.

    Time frame: After 12 months

  10. Quality of Life

    Improvement in quality of life was assessed using European Organisation for Research and Treatment of Cancer (EORTC) questionnaires: -The impact of treatment on Health-Related Quality of Life, functioning, and symptoms was evaluated using the EORTC QLQ-C30 v3. -Head and neck cancer-specific symptoms were evaluated using the EORTC QLQ-H\&N35. The symptom and QoL/function improvement rate was defined as the number (%) of patients with 2 consecutive assessments at least 14 days apart that showed a clinically meaningful improvement (a decrease from baseline score ≥10 or EORTC QLQ-C30 scales) in that symptom/function from baseline. For QLQ-H\&N35A a minimum clinically meaningful change was defined as a change in the score from baseline of \>10 for scales/items

    Time frame: After 12 months

  11. Duration of Response

    Duration of objective response in patients with objective response based on BICR assessments according to RECIST v1.1. Duration of response was the time from the first documentation of Complete response/Partial response (which was subsequently confirmed) until the date of progression, death, or the last evaluable RECIST assessment for patients that did not progress. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off (per RECIST v1.1 as assessed by BICR).

    Time frame: After 12 months

07

Results

Posted Jun 19, 2018

Participant flow

127 sites in 15 countries enrolled and screened patients. The study was conducted and managed by PRA, a contract research organization.

Participant flow — Overall Study
MilestoneMEDI4736 AND TREMELIMUMAB COMBINATIONMEDI4736Tremelimumab
Started1336767
Completed1170
Not completed1226067
Withdrew: Death, pi/sponsor decision, med history014
Withdrew: Withdrawal by subject336
Withdrew: Condition under investigation worsened1005046
Withdrew: Adverse event1728
Withdrew: Study specific discontinuation criteria221
Withdrew: Not treated022

Outcome measures

PrimaryObjective Response Rate at 6 Months

Objective response rate, primary analysis, based on BICR assessments according to RECIST v1.1. The number (%) of patients with a response excludes unconfirmed responses

Time frame:
After 6 months
Reported as:
Number · % participants
Objective Response Rate at 6 Months
% participantsMEDI4736 + TremelimumabMEDI4736Tremelimumab
Objective Response Rate at 6 Months7.7 (3.75 to 13.69)9.2 (3.46 to 19.02)1.6 (0.04 to 8.53)
PrimaryObjective Response Rate at 12 Months

Objective response rate (per RECIST 1.1 as assessed by blinded independent central review \[BICR\]) is defined as the number (%) of patients with a confirmed complete response or confirmed partial response and will be based on all treated patients who are PD-L1-positive with measurable disease at baseline per BICR. Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1. criteria are: Complete response \[CR\] = disappearance of all target lesions since baseline; and partial response \[PR\] = at least a 30% decrease in the sum of the diameters of target lesions.

Time frame:
After 12 months
Reported as:
Number · % participants
Objective Response Rate at 12 Months
% participantsMEDI4736 + TremelimumabMEDI4736Tremelimumab
Overall7.8 (3.78 to 13.79)9.2 (3.46 to 19.02)1.6 (0.04 to 8.53)
Current smoking/nicotine status - Total13.6 (2.91 to 34.91)14.3 (0.36 to 57.87)14.3 (0.36 to 57.87)
Current smoking/nicotine status - >10 pack years15.0 (3.21 to 37.89)14.3 (0.36 to 57.87)16.7 (0.42 to 64.12)
Current smoking/nicotine status - ≤10 pack years0 (0.00 to 84.19)—0 (0.00 to 97.50)
Former smoking/nicotine status -Total6.8 (2.54 to 14.25)8.2 (2.27 to 19.60)0 (0.00 to 8.04)
Former smoking/nicotine status - >10 pack years5.2 (1.08 to 14.38)9.1 (1.92 to 24.33)0 (0.00 to 10.89)
Former smoking/nicotine status - ≤10 pack years10.0 (2.11 to 26.53)6.3 (0.16 to 30.23)0 (0.00 to 26.46)
Smoking/nicotine status - Never5.3 (0.13 to 26.03)11.1 (0.28 to 48.25)0 (0.00 to 26.46)
HPV status - Positive5.4 (0.66 to 18.19)16.7 (3.58 to 41.42)0 (0.00 to 18.53)
HPV status - Negative8.7 (3.83 to 16.42)6.4 (1.34 to 17.54)2.2 (0.06 to 11.77)
SecondaryBest Objective Response

The best response a patient has had during their time in the study

Time frame:
After 12 months
Reported as:
Number · % participants
Best Objective Response
% participantsMEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Response - Total7.89.21.66.6
Response - Complete response (CR)0000
Response - Partial response (PR)7.89.21.66.6
Non-response (NR) - Total92.290.898.493.4
NR - Stable disease (SD) >=6 months (24 weeks)5.46.204.3
NR - Unconfirmed complete or partial response (PR)1.6000.8
NR - Stable disease3.96.203.5
NR - Progression64.364.669.865.8
NR - Progression-RECIST 1.1 progression45.746.254.047.9
NR - Progression-Death18.618.515.917.9
NR - Not evaluable-Total22.520.028.623.3
NR - Not evaluable-SD <6 months (24 weeks)20.216.919.019.1
NR - Not evaluable-Incomplete post baseline tests2.33.19.54.3
SecondaryDuration of Response - Participants Remaining in Response

Participants remaining in response - based on BICR assessments according to RECIST v1.1. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off.

Time frame:
After 12 months
Reported as:
Number · % participants
Duration of Response - Participants Remaining in Response
% participantsMEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Percentage remaining in response-3 months90.010010094.1
Percentage remaining in response-6 months70.066.710070.6
Percentage remaining in response-9 months58.366.7NA64.2
Percentage remaining in response-12 months46.7NANA53.5
Percentage of ongoing response50.066.710058.8
SecondaryTime to Response

Time to response in patients with objective response based on BICR assessments according to RECIST 1.1

Time frame:
After 12 months
Reported as:
Number · % participants
Time to Response
% participantsMEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Number of responders100100100100
Week 8, where response is first observed10.0005.9
Week 9, where response is first observed50.016.710041.2
Week 16, where response is first observed10.016.7011.8
Week 17, where response is first observed10.016.7011.8
Week 20, where response is first observed016.705.9
Week 24, where response is first observed10.016.7011.8
Week 25, where response is first observed10.016.7011.8
SecondaryTime to Onset of Response From First Dose

Time to onset of response in patients with objective response based on BICR assessments according to RECIST 1.1

Time frame:
After 12 months
Reported as:
Median · Months
Time to Onset of Response From First Dose
MonthsMEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Time to Onset of Response From First Dose2.0 (2 to 6)4.1 (2 to 6)1.8 (1.8 to 2)3.5 (2 to 6)
SecondaryDisease Control Rate (DCR)

Disease control rate (DCR) at 6 months based on BICR assessments according to RECIST v1.1. DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD). -Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following randomization. -Method 2: Patients who had a best objective response of CR or PR in the first 24 weeks or who had demonstrated SD for a minimum interval of 16 weeks following randomization.

Time frame:
After 6 months
Reported as:
Number · % participants
Disease Control Rate (DCR)
% participantsMEDI4736 + TremelimumabMEDI4736TremelimumabTotal
METHOD 1: Disease control (DC) at 6 months13.221.51.612.5
METHOD 1: No DC at 6 months86.878.598.487.5
METHOD 1: No DC at 6 months-Not evaluable/missing20.220.022.220.6
METHOD 2: DC at 6 months20.226.29.519.1
METHOD 2: No DC at 6 months79.873.890.580.9
METHOD 2: No DC at 6 months-Not evaluable/missing20.220.022.220.6
SecondaryDisease Control Rate (DCR)

Disease control rate (DCR) at 12 months based on BICR assessments according to RECIST v1.1. DCR at 6 months was evaluated using 2 different approaches to the length of stable disease (SD). -Method 1: Patients who had a best objective response of complete response (CR) or partial response (PR) within 24 weeks or had demonstrated SD for a minimum interval of 24 weeks following randomization. -Method 2: Patients who had a best objective response of CR or PR in the first 24 weeks or who had demonstrated SD for a minimum interval of 16 weeks following randomization.

Time frame:
After 12 months
Reported as:
Number · % participants
Disease Control Rate (DCR)
% participantsMEDI4736 + TremelimumabMEDI4736TremelimumabTotal
DC at 12 months10.112.31.68.6
No DC at 12 months89.987.798.491.4
No DC at 12 months-Not evaluable/missing20.220.022.220.6
SecondaryProgression-free Survival (PFS)

Progression status at 6 months based on BICR assessments according to RECIST v1.1 at time of Progression Free Survival (PFS) analysis. Progression was defined as the time from the data of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. -Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. -Progression death refers to death in the absence of RECIST 1.1 progression.

Time frame:
After 6 months
Reported as:
Number · % participants
Progression-free Survival (PFS)
% participantsMEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Progression-Total82.082.188.183.5
Total-RECIST 1.1 Progression57.959.767.260.7
RECIST 1.1 progression-Target Lesions43.643.355.246.4
RECIST 1.1 progression-Non-target lesions21.126.932.825.5
RECIST 1.1 progression-New lesions26.320.926.925.1
Progression-Death24.122.420.922.8
No progression-Total18.017.911.916.5
No progression-PD free and still being followed14.313.44.511.6
No progression-Censored on Study Day 11.5000.7
No progression-Withdrawn consent0.83.01.51.5
No progression- Censored death1.51.53.01.9
No progression- Discontinued study003.00.7
SecondaryProgression-free Survival (PFS)

Progression status at 12 months based on BICR assessments according to RECIST v1.1 at time of Progression Free Survival (PFS) analysis. Progression was defined as the time from the data of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdrew from therapy or received another anti-cancer therapy prior to progression. -Target Lesions, Non Target Lesions and New Lesions are not necessarily mutually exclusive categories. -Progression death refers to death in the absence of RECIST 1.1 progression.

Time frame:
After 12 months
Reported as:
Number · % participants
Progression-free Survival (PFS)
% participantsMEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Progression-Total88.783.689.687.6
Total-RECIST 1.1 Progression64.759.768.764.4
RECIST 1.1 progression-Target Lesions50.447.856.751.3
RECIST 1.1 progression-Non-target lesions23.328.432.827.0
RECIST 1.1 progression-New lesions27.123.923.925.5
Progression-Death24.123.920.923.2
No progression-Total11.316.410.412.4
No progression-PD free and still being followed6.811.93.07.1
No progression-Censored death3.803.02.6
No progression-Withdrawn consent0.84.51.51.9
No progression-Discontinued study003.00.7
SecondaryOverall Survival

Survival status at time of overall survival analysis. 'Still in survival follow-up' includes patients known to be alive at data cut-off. 'Terminated prior to death' includes patients with unknown survival status or patients who were lost to follow-up.

Time frame:
After 12 months
Reported as:
Number · % participants
Overall Survival
% participantsMEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Death64.765.776.167.8
Still in survival follow-up30.128.416.426.2
Terminated prior to death5.36.07.56.0
Terminated prior to death-Voluntary discon.5.36.04.55.2
Terminated prior to death-Other003.00.7
SecondaryQuality of Life

Improvement in quality of life was assessed using European Organisation for Research and Treatment of Cancer (EORTC) questionnaires: -The impact of treatment on Health-Related Quality of Life, functioning, and symptoms was evaluated using the EORTC QLQ-C30 v3. -Head and neck cancer-specific symptoms were evaluated using the EORTC QLQ-H\&N35. The symptom and QoL/function improvement rate was defined as the number (%) of patients with 2 consecutive assessments at least 14 days apart that showed a clinically meaningful improvement (a decrease from baseline score ≥10 or EORTC QLQ-C30 scales) in that symptom/function from baseline. For QLQ-H\&N35A a minimum clinically meaningful change was defined as a change in the score from baseline of \>10 for scales/items

Time frame:
After 12 months
Reported as:
Number · % patients
Quality of Life
% patientsMEDI4736 + TremelimumabMEDI4736Tremelimumab
EORTC QLQ-C30 Function-Physical12 (6.7 to 20.8)13.6 (6.4 to 26.7)5.1 (1.4 to 16.9)
EORTC QLQ-C30 Function-Role16.3 (10.0 to 25.5)16.7 (8.3 to 30.6)11.8 (4.7 to 26.6)
EORTC QLQ-C30 Function-Cognitive25 (16.2 to 36.4)29.4 (16.8 to 46.2)10.7 (3.7 to 27.2)
EORTC QLQ-C30 Function-Emotional13.5 (7.9 to 22.1)13.6 (6.4 to 26.7)2.6 (0.5 to 13.2)
EORTC QLQ-C30 Function-Social18.3 (11.0 to 28.8)15.2 (6.7 to 30.9)16.1 (7.1 to 32.6)
EORTC QLQ-C30 Symptom-Fatigue16.8 (10.9 to 25.0)17.3 (9.4 to 29.7)7.5 (3.0 to 17.9)
EORTC QLQ-C30 Symptom-Pain22.8 (15.4 to 32.4)20.8 (11.7 to 34.3)6.7 (2.3 to 17.9)
EORTC QLQ-C30 Symptom-Nausea/vomiting22.2 (12.5 to 36.3)16.7 (4.7 to 44.8)17.6 (6.2 to 41.0)
EORTC QLQ-C30 Global health status/QoL13.4 (8.3 to 20.9)7.3 (2.9 to 17.3)3.7 (1.0 to 12.5)
EORTC QLQ-H&N35 Scale-Pain16.7 (9.8 to 26.9)19.4 (9.8 to 35.0)8.3 (2.9 to 21.8)
EORTC QLQ-H&N35 Scale-Swallowing16.0 (9.4 to 25.9)13.3 (6.3 to 26.2)10.3 (4.1 to 23.6)
EORTC QLQ-H&N35 Scale-Senses17.8 (10.7 to 28.1)24.3 (13.4 to 40.1)23.1 (12.6 to 38.3)
EORTC QLQ-H&N35 Scale-Speech20.2 (13.3 to 29.4)9.8 (4.3 to 21.0)19.6 (10.7 to 33.2)
EORTC QLQ-H&N35 Scale-Social eating21.3 (13.7 to 31.4)20.0 (10.9 to 33.8)15.0 (7.1 to 29.1)
EORTC QLQ-H&N35 Scale-Social contact22.6 (14.0 to 34.4)5.9 (1.6 to 19.1)13.0 (4.5 to 32.1)
EORTC QLQ-H&N35 Scale-Sexuality16.2 (9.5 to 26.2)9.5 (3.8 to 22.1)9.5 (3.8 to 22.1)
SecondaryDuration of Response

Duration of objective response in patients with objective response based on BICR assessments according to RECIST v1.1. Duration of response was the time from the first documentation of Complete response/Partial response (which was subsequently confirmed) until the date of progression, death, or the last evaluable RECIST assessment for patients that did not progress. An ongoing response was defined as a patient who had documented objective response and was still alive and progression-free at the time of the data cut-off (per RECIST v1.1 as assessed by BICR).

Time frame:
After 12 months
Reported as:
Number · Participants
Duration of Response
ParticipantsMEDI4736 + TremelimumabMEDI4736TremelimumabTotal
No. progressed or died within 12 months5207
No. progressed or died after 12 months0000

Adverse events

Collected over AEs and SAEs were collected from time the informed consent was signed through 90 days after the last dose of the last study treatment or until another therapy was initiated.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MEDI4736 AND TREMELIMUMAB COMBINATION86/133 (64.7%)59/133 (44.4%)110/133 (82.7%)
MEDI473644/67 (65.7%)18/65 (27.7%)52/65 (80%)
Tremelimumab51/67 (76.1%)25/65 (38.5%)59/65 (90.8%)
Most frequent serious events
Showing 10 of 111
Most frequent serious events
EventMEDI4736 AND TREMELIMUMAB COMBINATIONMEDI4736Tremelimumab
DiarrhoeaGastrointestinal disorders5/1330/655/65
PneumoniaInfections and infestations9/1331/651/65
DysphagiaGastrointestinal disorders1/1331/652/65
Pneumonia bacterialInfections and infestations0/1330/652/65
DizzinessNervous system disorders0/1332/650/65
DyspnoeaRespiratory, thoracic and mediastinal disorders4/1331/652/65
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders3/1330/652/65
Lung infectionInfections and infestations4/1331/651/65
DehydrationMetabolism and nutrition disorders4/1331/651/65
HypercalcaemiaMetabolism and nutrition disorders4/1331/650/65
Most frequent other events
Showing 10 of 41
Most frequent other events
EventMEDI4736 AND TREMELIMUMAB COMBINATIONMEDI4736Tremelimumab
FatigueGeneral disorders25/13319/6512/65
NauseaGastrointestinal disorders18/1337/6518/65
DiarrhoeaGastrointestinal disorders27/13312/6514/65
Decreased appetiteMetabolism and nutrition disorders25/13310/6510/65
PyrexiaGeneral disorders16/1335/6512/65
DyspnoeaRespiratory, thoracic and mediastinal disorders14/13310/6512/65
AnaemiaBlood and lymphatic system disorders20/13311/6511/65
AstheniaGeneral disorders21/13310/658/65
HypothyroidismEndocrine disorders15/1339/656/65
ConstipationGastrointestinal disorders18/1339/658/65

Baseline characteristics

Full analysis set - all randomized patients

Age, Categorical
Age, Categorical(Participants)MEDI4736 + TremelimumabMEDI4736TremelimumabTotal
<=18 years0000
Between 18 and 65 years884642176
>=65 years45212591
Age, Continuous
Age, Continuous(years)MEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Median62 (26 to 81)62 (23 to 82)61 (42 to 77)61 (23 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)MEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Female20131447
Male1135453220
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MEDI4736 + TremelimumabMEDI4736TremelimumabTotal
American Indian or Alaska Native0000
Asian4329
Native Hawaiian or Other Pacific Islander0000
Black or African American63110
White1155857230
More than one race0000
Unknown or Not Reported83718
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Ethnic group - Hispanic or Latino82515
Ethnic group - Not Hispanic or Latino1196458241
Ethnic group - Total1276663256
Asian ethnic group - Asian (not Chinese/Japanese)3216
Asian ethnic group - Chinese1113
Asian ethnic group - Total4329
Unknown or not reported2024
Negative PD-L1 status
Negative PD-L1 status(Participants)MEDI4736 + TremelimumabMEDI4736TremelimumabTotal
PD-L1 negative patients1336767267
HPV status
HPV status(Participants)MEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Positive39181875
Negative944949192
Use of nicotine (other than cigarettes)
Use of nicotine (other than cigarettes)(Participants)MEDI4736 + TremelimumabMEDI4736TremelimumabTotal
Yes1102
No1326667265

2 further baseline measures are reported on the registry.

08

Study locations

125 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Yuma, Arizona 85364, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Downey, California 90241, United States
  • Research Site
    Duarte, California 91010-3012, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Long Beach, California 90813, United States
  • Research Site
    Los Angeles, California 90033, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    San Francisco, California 94115, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Augusta, Georgia 30912, United States
  • Research Site
    Macon, Georgia 31201, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Evanston, Illinois 60201, United States
  • Research Site
    Lexington, Kentucky 40536-0001, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Baltimore, Maryland 21204, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Southfield, Michigan 48075, United States
  • Research Site
    Rochester, Minnesota 55905-0001, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Lebanon, New Hampshire 03756, United States
  • Research Site
    Bronx, New York 10467, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Stony Brook, New York 11794, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Winston-Salem, North Carolina 27157, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Bethlehem, Pennsylvania 18015, United States
  • Research Site
    Pittsburgh, Pennsylvania 15232, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Knoxville, Tennessee 37909, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Arlington, Texas 76012, United States
  • Research Site
    Austin, Texas 78701, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Tweed Heads, 2485, Australia
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Kortrijk, 8500, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Calgary, Alberta T2N 2T9, Canada
  • Research Site
    Moncton, New Brunswick E1C 6Z8, Canada
  • Research Site
    London, Ontario N6A 4L6, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Olomouc, 775 20, Czechia
  • Research Site
    Zlin, 762 75, Czechia
  • Research Site
    Angers, 49933, France
  • Research Site
    Bordeaux, 33604, France
  • Research Site
    Brest, 29229, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Le Mans, 72000, France
  • Research Site
    Lille cedex, 59020, France
  • Research Site
    Lorient cedex, 56322, France
  • Research Site
    Lyon Cedex 08, 69373, France
  • Research Site
    Montpellier, 34298, France
  • Research Site
    Nice, 6189, France
  • Research Site
    Rouen, 76038, France
  • Research Site
    Saint Brieuc, 22015, France
  • Research Site
    St Grégoire, 35768, France
  • Research Site
    Strasbourg Cedex, 67085, France
  • Research Site
    Toulouse Cedex 9, 31059, France
  • Research Site
    Villejuif Cedex, 94805, France
  • Research Site
    Batumi, 6010, Georgia
  • Research Site
    Batumi, 6400, Georgia
  • Research Site
    Tbilisi, 0144, Georgia
  • Research Site
    Tbilisi, 0177, Georgia
  • Research Site
    Tbilisi, 0179, Georgia
  • Research Site
    Berlin, 12203, Germany
  • Research Site
    Halle, 06120, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Budapest, 1077, Hungary
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Gyula, 5700, Hungary
  • Research Site
    Györ, 9024, Hungary
  • Research Site
    Kecskemét, 6000, Hungary
  • Research Site
    Miskolc, 3526, Hungary
  • Research Site
    Zalaegerszeg, 8900, Hungary
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Petach-Tikva, 4941492, Israel
  • Research Site
    Tel Hashomer, 52621, Israel
  • Research Site
    Daegu, 42601, Korea, Republic of
  • Research Site
    Goyang-si, 10408, Korea, Republic of

Showing the first 100 of 125 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Siu LL, Even C, Mesia R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Brana I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. PubMed 30383184 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Sep 2016, 17 months.

Results were first posted in Jun 2018, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2014
First posted
Dec 18, 2014
StartActual
Apr 15, 2015
Primary completionActual
Sep 26, 2016
CompletionActual
Jul 6, 2020
Results first posted
Jun 19, 2018
Last update
Sep 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02319044
Lead sponsor
AstraZeneca
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Dec 18, 2014
Start date
Apr 15, 2015
Primary completion
Sep 26, 2016
Completion
Jul 6, 2020
Results posted
Jun 19, 2018
Last update
Sep 29, 2020

Study contacts

Magdalena Wrona
study director · Medical Scientist AstraZeneca Magdalena.Wrona@astrazeneca.com
Lillian Siu, MD
principal investigator · Princess Margaret Hospital in Toronto, Ontario

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion